Background {#Sec1}
==========

The drug design and development process involves the use of a variety of computational techniques, such as (quantitative) structure-activity relationships \[(Q)SAR\], molecular mechanics, quantum mechanics, molecular dynamics, and drug-receptor docking \[[@CR1], [@CR2]\]. (Q)SAR studies are based on the premise that biological response is a function of the chemical structure \[[@CR3], [@CR4]\]. (Q)SAR models reveal a relationship between the structural characteristics of the compounds and their biological activity or environmental behavior \[[@CR5], [@CR6]\]. (Q)SAR models predict chemical behavior and simulate adverse effects in laboratory animals, tissues, and cells directly from the chemical structure. This will naturally minimize the need to conduct animal tests so as to comply with the regulatory requirements for human health and eco-toxicology endpoints \[[@CR7], [@CR8]\]. The main hypothesis in (Q)SAR is that similar chemicals have similar properties, and even a minor structural change(s) will result in a change in property value(s) \[[@CR9]\]. SAR represents classification models that are used when an empirical property is characterized in a (+1/−1) manner, such as soluble/insoluble, active/inactive, toxic/non-toxic, permeable/impermeable, inhibitor/non-inhibitor, ligand/non-ligand, substrate/non-substrate, mutagen/non-mutagen, polar/non-polar, or carcinogen/non-carcinogen \[[@CR10]--[@CR15]\]. *In silico* screening constitutes a vital cost-effective high-throughput process for providing a rapid indication of potential hazards for use in lead prioritization \[[@CR16]\].

Machine learning (ML) constitutes a vital area of artificial intelligence (AI) in which models are simply generated by extracting rules and functions from relatively large datasets. ML comprises diverse methods and algorithms such as decision trees, general CHAID models, *k*-nearest neighbors, random forests, Bayesian methods, Gaussian processes, artificial neural networks (ANN), artificial immune systems, kernel algorithms, and support vector machines (SVMs). ML algorithms extract relevant information from empirical dataset through computational/statistical techniques and generate a set of rules, functions, or procedures that allow them to predict the properties of novel objects which have not been included in the learning set. (Q)SAR models derived through ML algorithms are subsequently applied during the drug development process so as to optimize the therapeutic activity, target selectivity, and related physico-chemical and biological properties of the selected molecules \[[@CR10], [@CR17], [@CR18]\]. The advantage of AI approaches is that they can be easily applied to learn from examples and to evolve suitable prophesy models in spite of the limited understanding of the underlying molecular processes. The AI approach is also beneficial whenever computational simulations based on fundamental physical models are too expensive to perform \[[@CR19], [@CR20]\].

AIDS is one of the most urgent global health problems and is the leading cause of death in Africa and the fourth leading cause of death across the world. Highly active antiretroviral therapy (HAART) has gained considerable success in Western countries. The anti-HIV drug evolution process resembles a crystal ball and involves a plenty of astonishment, expectations, and disappointments. Unfortunately, we continue to be dependent on the predictions of the crystal ball. All of the currently available anti-HIV drugs are far from ideal, and we still face problems of acute and chronic side effects, patient compliance issues, drug resistance, cost, and potency. Hopes of long-term management and eradication depend on increasing available therapeutic options \[[@CR21], [@CR22]\].

Purine nucleoside analogs (PNAs) constitute an important group of cytotoxic drugs for the treatment of neoplastic and autoimmune diseases \[[@CR23]\]. 9-\[4-α-(Hydroxymethyl)cyclopent-2-ene-1-α-yl\]guanine (CBV), (−)-β-D-(2R,4R)-1,3-dioxolane-guanosine (DXZ), 3′-azido-3′deoxy-guanosine (AZG), and 2′-C-methylguanosine are all known for their reverse transcriptase inhibiting activity \[[@CR24]\]. 3,9-Dihydro-9-dioxo-5H-imidazo(1,2-A) purine nucleosides synthesized from these nucleosides have shown improved anti-HIV activity \[[@CR25]\].

In the present study, models of diverse nature have been developed through decision tree (DT), random forest (RF), support vector machine (SVM), and moving average analysis (MAA) using molecular descriptors (MDs) as independent variables for the prediction of the anti-HIV activity of purine nucleoside analogs in human peripheral blood mononuclear (PBM) cells.

Methods {#Sec2}
=======

Dataset {#Sec3}
-------

A dataset comprising 36 purine nucleoside analogs was selected for the present investigation (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). The anti-HIV activity of these analogs in human PBM cells has been reported in terms of EC~50~ (effective concentration against 50 % of cell population) by Amblard et al. \[[@CR25]\]. The nucleoside analog DXZ possessing an EC~50~ value of 0.51 μM is well known for its anti-HIV activity. DXZ was considered as a reference compound \[[@CR24]\]. Accordingly, analogs possessing EC~50~ values of ≤0.51 μM were considered to be active and analogs possessing EC~50~ values of \>0.51 μM were considered to be inactive for the purpose of the present study.Fig. 1Basic structures of purine nucleoside analogs from serial number 1 to 36 \[[@CR25]\]Table 1Relationship between molecular descriptors and anti-HIV activity in human PBM cellsSerial numberBasic structure of compoundSubstituent (R)A2A4A23A37Anti-HIV activity in human PBM cells (EC~50~)PredictedReported \[[@CR25]\]A2A4A23A371I3-\[4-(Hydroxymethyl)-2-cyclopent-1-yl\]0.9193.2879.612.16++±−+2I3-(β-D-1,3-Dioxolanyl)0.9223.19.9822.254++±−+3I3-(3-Azido-2,3-dideoxy-β-D-erythro-pentofuranosyl)0.9034.59950.5992.197+++−+4I3-(β-D-2-C-Methyl-ribofuranosyl)0.8480.001615.5212.332−−−−−5II4-MeO-Ph0.97311.6664.8661.596−−−−−6II4-Me-Ph0.97211.155.3381.614−−−−−7II4-Br-Ph0.9711.5453.8831.631−−−−−8II4-NEt~2~-Ph0.97614.05143.5831.531−−+++9II4-NMe~2~-Ph0.97612.59743.441.573−−+++10II2-Thiophenyl0.9689.9995.9371.655−−−−−11II3-Thiophenyl0.96910.6375.2231.641−−−−−12IIIEt0.9456.1577.3071.938−−−−−13IIIPh0.9719.8692.3131.674−−−−−14III4-MeO-Ph0.97411.6024.8491.627−−−−−15III3-MeO-Ph0.97410.5455.381.652−−−−−16III2-MeO-Ph0.979.8346.1211.678−−−−−17III4-Me-Ph0.97311.0815.4361.648−−−−−18III4-Cl-Ph0.97111.3074.7121.661−−−−−19III4-F-Ph0.97110.9295.1321.655−−−−−20III2,4-F-Ph0.97110.96935.941.672−−±−−21III4-NEt~2~-Ph0.97413.45844.5661.555−−+++22III4-NMe~2~-Ph0.97612.54444.5991.601−−+−−23III2-Thiophenyl0.9699.926.0491.69−−−−−24III3-Thiophenyl0.979.9515.2611.675−−−−−25III4-N~3~-Ph0.96112.0914.5321.611−−−−−26III4-CN-Ph0.97512.574.8931.626−−−−−27IVPh0.9390.5666.4941.645−−−−−28IV4-MeO-Ph0.8891.92339.1431.609−−±−−29IV4-NEt~2~-Ph0.9074.048357.4241.551+++++30IV4-NMe~2~-Ph0.9012.76344.7121.589+++++31VEt0.8780.018993.8431.986−−−−−32V4-MeO-Ph0.9370.9821972.7931.663−−−−−33V4-NEt~2~-Ph2.3450.9416,083.2291.594−−−−−34V4-NMe~2~-Ph0.9830.93912,785.1211.639−−−−−35V2-Thiophenyl0.1230.9232081.6891.72−−−−−36V3-Thiophenyl0.1220.9232059.0541.706−−−−−+, active; −, inactive; ±, transitional

Molecular descriptors {#Sec4}
---------------------

The MDs used in the current study include constitutional, physico-chemical, topostructural, topochemical, and topological charge indices, walk and path counts, information-based indices, and a wide variety of 3D descriptors. The majority of 2D and 3D MDs utilized in the present study were calculated using the Dragon software (version 5.3). Most of these MDs are reviewed in the textbook by Todeschini and Consonni \[[@CR26]\]. An in-house computer program was also employed to calculate MDs which were not included in the Dragon software. Initially, MDs with significant degenerate values were omitted from the large pool of MDs calculated through both the Dragon software and the in-house computer program. For the remaining MDs, a pairwise correlation analysis was carried out (one of any two indices with *r* ≥ 0.90 was excluded to minimize redundant information). The abovementioned exclusion technique was utilized to decrease the correlation and collinearity between MDs. Finally, 60 MDs, enlisted in Table [2](#Tab2){ref-type="table"}, were short-listed for the development of models.Table 2List of molecular descriptorsCodeName of descriptorA1Eccentricity index, ECCA2Spherocity index, SPHA3Molecular connectivity topochemical index, *χ* ^*A*^A4Shape profile no. 20, SP20A5Shape profile no. 07, SP07A6Shape profile no. 08, SP08A7Eccentric adjacency topochemical indexA8Radial distribution function - 10.5/weighted by atomic masses, RDF105mA9Second Zagreb index M2, ZM2A10Augmented eccentric connectivity topochemical index, ^*A*^ *ξ* ^*c*^A11Mean information content on the distance magnitude, IDMA12Molecular profile no. 10, DP10A13Molecular profile no. 11, DP11A14Molecular profile no. 12, DP12A15Molecular profile no. 13, DP13A16Molecular profile no. 14, DP14A17Radius of gyration (mass weighted), RGyrA18Eccentric connectivity topochemical index, *ξ* ^*c*^A19Connective eccentricity topochemical index, *C* ^*ξ*^A20Average vertex distance degree, VDAA21Mean square distance index (Balaban), MSDA22Schultz molecular topological index, SMTIA23Superaugmented pendentic topochemical index-4, ^*SA*^ *∫* ^*P-*4*c*^A24Gutman MTI by valence vertex degrees, GMTIVA25Xu index, XuA26Mean Wiener index, WAA27Superadjacency topochemical index, *∫* ^*AC*^(*G*)A28Harary *H* index, HarA29Quasi-Wiener index (Kirchhoff number), QWA30First Mohar index, TI1A31Weiner's topochemical index, *W* ~*c*~A32Reciprocal hyper-detour index, RwwA33Distance/detour index, D/DA34All-path Wiener index, WapA35Superaugmented eccentric connectivity topochemical index-3, ^*SAc*^ *ξ* ^*c*^ ~3~A36Wiener-type index from *Z*-weighted distance matrix (Barysz matrix), WhetZA37Balaban-type index from *Z*-weighted distance matrix (Barysz matrix), JhetZA38Maximal electrotopological negative variation, MAXDNA39Molecular electrotopological variation, DELSA40Superaugmented eccentric connectivity topochemical index-4, ^*SAc*^ *ξ* ^*c*^ ~4~A41Three-path Kier alpha-modified shape index, S3KA42Centralization, CENTA43Distance/detour ring index of order 9, D/Dr09A44Molecular connectivity index, *χ*A45Eigenvalue 11 from edge adjacency matrix weighted by resonance integrals, EEig11rA46Average geometric distance degree, AGDDA47Absolute eigenvalue sum on geometry matrix, SEigA48Eccentric adjacency index, *ξ* ^*Α*^A493D-MoRSE - signal 26/unweighted, Mor26uA503D-MoRSE - signal 25/weighted by atomic Sanderson electronegativities, Mor25eA51Augmented eccentric connectivity index, ^*A*^ *ξ* ^*c*^A52First component size directional WHIM index/unweighted, L1uA53K global shape index/weighted by atomic Sanderson electronegativities, KeA54Superpendentic index, ∫*P*A55Mean information content on the leverage magnitude, HICA56*H* total index/weighted by atomic van der Waals volumes, HTvA57*R* maximal autocorrelation of lag 1/weighted by atomic Sanderson electronegativities, R1e+A58*R* total index/weighted by atomic polarizabilities, RTpA59Superaugmented eccentric connectivity index-1, ^*SA*^ *ξ* ^*c*^ ~1~A60Weiner's index, *W*Most of the Dragon descriptors are largely defined in ref. \[[@CR26]\]

Statistical methods {#Sec5}
-------------------

### Decision tree {#Sec6}

DT is a common method that provides both classification and predictive functions simultaneously. A single DT was grown for the prediction of anti-HIV activity and to identify the importance of various MDs used for the present study. A cutoff value dividing the compounds of the dataset into active and inactive with regard to anti-HIV activity was assigned to each MD for every compound. Then, a single MD is identified that split the entire training set into two or more homogenous subsets and shows the lowest possible false assignment before being chosen as parent node. The molecules at each parent node are classified, based on the MD value, into two child nodes, and the resulting child nodes or subsets are split into sub-subsets, generally using different MDs. The majority vote of the molecules reaching the same terminal node in the training set decides the prediction for a molecule to reach a given terminal node. In this manner, DT created an interactive branching topology in which the branch taken at each intersection is determined by a rule related to a MD of the molecule, and lastly, each terminating leaf of the tree is assigned to a particular category, i.e., A (active) or B (inactive) \[[@CR27]--[@CR30]\]. In the present study, RPART library was added in R program (version 2.10.1) to grow DT.

### Random forest {#Sec7}

RF is a well-known ensemble of unpruned trees generated through the systematic use of bootstrap samples of the training data for building forests (multiple trees) and random subsets of variables to facilitate the best possible bifurcation at each node \[[@CR31], [@CR32]\]. In the present study, the RFs were grown with the R program (version 2.10.1) using the random forest library.

### Support vector machine {#Sec8}

SVM is a relatively new classification technique. SVM involves drawing a boundary between groups of samples that fall into different classes. The SVM methodology comprised reducing the pool of 30 descriptors to a smaller size by eliminating the related variables, followed by development of classification models \[[@CR33], [@CR34]\]. Statistica v. 7.0 was used for the generation of SVM models. The classification models were generated using the training set of compounds followed by the validation of the best model using the test set of compounds \[[@CR35]\]. Every third compound of the dataset was included in the test set. SVM model validity was also checked by cross-validation, i.e., leave-one-out method. SVM models were also validated by tenfold cross-validation. The kernel type that was adopted in the present work was the polynomial function. The first task was the assignment of each molecule to one class, namely 'actives' or 'inactives' based on the cutoff value (EC~50~ = 0.51 μM) of the reference compound.

### Moving average analysis {#Sec9}

MAA was utilized so as to facilitate the construction of single MD-based models for predicting the anti-HIV activity of purine nucleoside analogs. For the selection and evaluation of range-specific characteristics, exclusive activity ranges were determined from the frequency distribution of therapeutic response level. This was accomplished by initially plotting the relationship between index values and anti-HIV activity and subsequently identifying the active range by scrutinizing the resultant data by maximization of moving average with regard to active purine nucleoside analogs (\<35 % = inactive, 35 % to 65 % = transitional, and \>65 % = active) \[[@CR36]\]. Biological activity was assigned to each analog involved in the dataset, which was subsequently compared with the reported anti-HIV activity (Table [1](#Tab1){ref-type="table"}). Average values of EC~50~ and selectivity index (SI) were calculated for each range of the proposed models.

### Model validation {#Sec10}

DT-based models were validated using the tenfold cross-validation (CV) method \[[@CR37]\]. The performance of the proposed models was evaluated by calculating the overall accuracy of prediction, sensitivity, specificity, non-error rate (arithmetic mean of sensitivity and specificity) \[[@CR38], [@CR39]\], and Matthews correlation coefficient (MCC) \[[@CR40]\]. MCC is generally regarded as being one of the best statistical techniques which account for both over- and underprediction. MCC takes both sensitivity and specificity into account, and its value ranges from −1 to +1. Higher values of MCC indicate better predictions \[[@CR41], [@CR42]\]. The statistical importance of MDs used in building predictive models was also appraised by intercorrelation analysis. The degree of correlation was appraised by Spearman's rank correlation coefficient '*r*'. Pairs of MDs with *r* ≥ 0.97 are considered to be highly inter-correlated while those with 0.68 ≤ *r* ≤ 0.97 to be appreciably correlated; MDs with 0.36 ≤ *r* ≤ 0.67 are weakly correlated whereas the pairs of MDs with low *r* values (\<0.35) are not inter-correlated \[[@CR43], [@CR44]\].

Results and discussion {#Sec11}
======================

AIDS is the fourth leading cause of death worldwide. Inhibition of the human immunodeficiency virus and sustained suppression of viral replication reduce morbidity and prolong life in patients with HIV infection. This virus is therefore a major target for the structure-based inhibitors design.

Finding that the structure of a molecule has an important role in its therapeutic activity coupled with the need for safer potent drugs to be developed with minimum animal sacrifice, expenditure, and time loss has led to the origin of structure-activity relationship (SAR) studies \[[@CR45]\]. The inherent problem in the development of a suitable correlation between chemical structures and biological activity can be attributed to the non-quantitative nature of chemical structures. MDs translate chemical structures into characteristic numerals and facilitate (Q)SAR studies \[[@CR46], [@CR47]\].

In the present study, the relationship between anti-HIV activity and the structure of purine nucleoside analogs has been investigated and suitable models developed using diverse classification techniques, i.e., DT, RF, SVM, and MAA. DT was built from a set of 60 MDs enlisted in Table [2](#Tab2){ref-type="table"}. The MD at the originating node is the most significant, and the significance of MD decreases with the gradual increase in the tree height \[[@CR27]--[@CR30]\]. The classification of purine nucleoside analogs as inactive and active using a single tree, based on the Balaban-type index from *Z*-weighted distance matrix, A37, *JhetZ index*, and mean information content on the distance magnitude, A11, *IDM index*, has been depicted in Fig. [2](#Fig2){ref-type="fig"}. The DT identified the Balaban-type index from *Z*-weighted distance matrix, A37, *JhetZ index*, as the most important index.Fig. 2A decision tree for distinguishing active purine nucleoside analogs (A) from inactive analogs (B)

A37, i.e., the Balaban-type index from *Z*-weighted distance matrix, *JhetZ index*, is based on the Barysz matrix and was developed by Barysz et al. It may be expressed as per the following:$$\documentclass[12pt]{minimal}
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where *S*~*i*~*S*~*j*~ represents the product of the distance sums of the adjacent pairs of vertices *i* and *j* in a graph *G*. The cycloatomic number of the graph is represented by *μ*, and it indicates the number of independent cycles in the graph \[[@CR48], [@CR49]\].

The DT classified the analogs with an accuracy of \>99.9 % in the training set. The sensitivity, specificity, non-error rate, overall accuracy of prediction, and MCC of the tenfold cross-validated set was of the order of 75 %, 93 %, 84 %, 89 %, and 0.68, respectively (Table [3](#Tab3){ref-type="table"}). A high value of MCC simply indicates the robustness of the proposed DT-based model.Table 3Confusion matrix for anti-HIV activity of purine nucleoside analogs in human PBM cellsModelDescriptionRangesNumber of compounds predictedSensitivity (%)Specificity (%)Non-error rate (%)Overall accuracy of prediction (%)MCCActiveInactiveDecision treeTraining setActive0800100100100\>99.91.00Inactive0028Tenfold cross-validated setActive0602759384890.68Inactive0226Random forestActive050362.58975.7830.52Inactive0325Support vector machineTraining setActive040266.710083.3930.78Inactive0021Test setActive0101508668780.36Inactive0106The recognition rate of decision tree-, random forest-, and support vector machine-based models is also shown

A11, i.e., mean information content on the distance magnitude, *IDM index*, is one of the information indices reported by Bonchev et al. It may be expressed as per the following:$$\documentclass[12pt]{minimal}
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where *W* is the Wiener index, *k*~*n*~ is the number of distances of equal *n* value in the triangular submatrix *D*, and *G* is the maximum distance value \[[@CR50]\].

The RFs were grown utilizing 60 MDs as enlisted in Table [1](#Tab1){ref-type="table"}. The RF classified purine nucleoside analogs with regard to anti-HIV activity with an accuracy of 83 % and the out-of-bag (OOB) estimate of error was 17 %. The sensitivity, specificity, non-error rate, accuracy of prediction, and MCC value of the RF-based model for the tenfold cross-validated set were found to be 62.5 %, 89 %, 75.7 %, 83 %, and 0.52, respectively (Table [3](#Tab3){ref-type="table"}). A high value of MCC simply indicates the robustness of the proposed RF-based model.

SVM-based classification models were built utilizing a small pool of topological descriptors as specified in the [Methods](#Sec2){ref-type="sec"} section. The dataset was divided into a training and a test set based on a random test set selection comprising 27 compounds in the training and 9 compounds in the test set, respectively. The models were built using the training set molecules and subsequently validated by test set molecules. The SVM model for the training set resulted in a specificity of 100 % and an accuracy of prediction of 93 %. The sensitivity, specificity, non-error rate, overall accuracy of prediction, and MCC of the test set was of the order of 50 %, 86 %, 68 %, 78 %, and 0.36, respectively (Table [3](#Tab3){ref-type="table"}).

Four single index-based models were developed using MAA (Table [4](#Tab4){ref-type="table"}). The Balaban-type index from *Z*-weighted distance matrix: *index* A37, identified as the most important index by the decision tree, was used to construct a model for the prediction of the anti-HIV activity of purine nucleoside analogs. Three more indices, i.e., spherocity index, SPH, A2; shape profile no. 20, SP20, A4; and superaugmented pendentic topochemical index-4, ^*SA*^*∫*^*P-*4*c*^, A23, were also used to develop the models for predicting the anti-HIV activity of purine nucleoside analogs.Table 4Proposed MAA models for the prediction of anti-HIV activity of PNAs in human PBM cellsDescriptorNature of range in the proposed modelDescriptor valueNumber of compounds in each rangeSensitivity (%)Specificity (%)Non-error rate (%)Overall accuracy of prediction (%)MCCAverage EC~50~ (μM) of correctly predicted compounds in each rangeAverage SI of correctly predicted compounds in each rangeTotalCorrectly predictedA2Lower inactive\<0.901336310081.591.70.7567.115.205Active0.901 to 0.922550.182825.741Upper inactive\>0.922282533.61366.665A4Lower inactive\<2.76996310081.591.70.7578.8556.544Active2.76 to 4.599550.182825.741Upper inactive\>4.599221917.4743.186A23Lower inactive\<9.611818100969896.90.9118.05636.560Transitional9.61 to 43.434NA4.138102.32Active43.44 to 357.424760.141859.542Upper inactive\>357.42477100100A37Active1.531 to 1.589556310081.591.70.750.134920.339Inactive\>1.589242137.20131.408*NA* not applicable

A2, i.e., spherocity index, SPH, is one of the geometrical descriptors given by Robinson et al. and may be expressed as:$$\documentclass[12pt]{minimal}
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where *λ*~1~, *λ*~2~, and *λ*~3~ are the eigenvalues of the auto-covarience matrix used in the principal component analysis of the molecule. The Ω~SPH~ value ranges from unity for totally spherical molecules to zero for totally flat molecules \[[@CR51]\].

A4, i.e., shape profile no. 20, SP20, is one of the Randic molecular profiles described by Randic and may be expressed as:$$\documentclass[12pt]{minimal}
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where *N* is a constant indicating the size of the system. ^1^*R*, ^2^*R*, ^3^*R*... are the averages of the row sums in the ^1^*D*, ^2^*D*, ^3^*D*... matrix, respectively. *D* is the geometry distance matrix of a structure \[[@CR52]\].

A23, i.e., superaugmented pendentic topochemical index-4, is the topochemical version of the topological descriptor (superaugmented pendentic index-4) reported by Dureja et al. \[[@CR53]\]. Superaugmented pendentic index-4 is expressed as:$$\documentclass[12pt]{minimal}
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Superaugmented pendentic topochemical index-4 may be defined as the summation of the quotients of the product of all the non-zero row elements in the chemical pendent matrix and product of chemical adjacent vertex degrees and the fourth power of the chemical eccentricity of the concerned vertex for all vertices in a hydrogen-suppressed chemical molecular graph and may be expressed as:$$\documentclass[12pt]{minimal}
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where *p*~*ic*~ is the chemical pendenticity and is obtained by multiplying all the non-zero row elements in the chemical pendent matrix, *∆Pc*, of a chemical graph (*G*~*k*,~*n*)*c. ∆Pc* is a sub-matrix of the chemical distance matrix and is obtained by retaining the columns corresponding to pendent vertices. *m*~*ic*~ is the augmented chemical adjacency and is defined as the product of chemical degrees of all the vertices *v*~*j*~ adjacent to vertex *v*~*i*~. *e*~*ic*~ is the chemical eccentricity of vertex *v*~*i*~, and *n* is the number of vertices in graph *G* \[[@CR54]--[@CR56]\].

The results of the intercorrelation analysis (Table [5](#Tab5){ref-type="table"}) reveal that the pairs A2:A23 and A23:A37 were not correlated while the pairs A4:A23, A4:A37, and A2:A37 were found to be weakly correlated. The accuracy of prediction for all the four MAA-based models varies from 91.7 to 96.9 %, indicating high predictability (Table [4](#Tab4){ref-type="table"}).Table 5Intercorrelation matrixA2A4A23A37A21.000.85−0.13−0.62A41.00−0.39−0.47A231.00−0.11A371.00

The average EC~50~ value of the correctly predicted analogs in the active ranges in MAA-based models varied from 0.134 to 0.182 μM. Such a low average EC~50~ value signifies high potency of the active ranges (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Average EC~50~ of anti-HIV activity of correctly predicted PNAs in various ranges of MAA-based models

Drug safety evaluation is the key part of drug discovery and development process to identify those that have an appropriately balanced safety-efficacy profile for a given indication \[[@CR57]\]. The therapeutic index (TI), certain safety factor (CSF), protective index (PI), therapeutic window (TW), and selectivity index (SI) are some of such important parameters that can be used to achieve this balance. TI may be defined as the ratio of LD~50~/ED~50~, where LD~50~ is defined as the single dose of a therapeutic agent that can be likely to cause death in 50 % of the animal population and ED~50~ is defined as the single dose of a therapeutic agent that can be likely to cause a particular effect to occur in 50 % of the animal population \[[@CR58]--[@CR60]\]. Similarly, SI is calculated for a drug molecule in the case of cell studies, and it may be defined as the ratio of CC~50~ to EC~50~, where CC~50~ and EC~50~ represent cytotoxic and effective concentrations, respectively. It is an indirect measure of the safety of a drug. A high value of SI simply indicates low toxicity and more safety. A high value of SI is a desirable property for any drug candidate so as to minimize toxicity. Therefore, such safety parameters should be determined in the initial stages of the drug discovery process to avoid much costlier late-stage failures \[[@CR61]\]. Active ranges of the proposed MAA-based models exhibited high degree of selectivity towards infected human PBM cells as indicated by a greater value of SI for active ranges compared to inactive ranges (Fig. [4](#Fig4){ref-type="fig"}). As a consequence, active ranges identified by MAA models have both the desired requirements of a drug molecule, i.e., high potency and safety. Model validation by confusion matrix shows the sensitivity of the models of the order of 63 % to 100 % (Table [4](#Tab4){ref-type="table"}). High values of MCC simply indicate the robustness of the proposed MAA-based models.Fig. 4Average SI against PBM cells of correctly predicted PNAs in various ranges of MAA-based models

The present modeling studies may be of great utility for providing lead molecules through exploitation of active ranges in single MD-based models. The proposed models are unique and differ widely from conventional QSAR models. Both systems of modeling have their advantages and limitations. In the instant modeling, the system adopted has a distinct advantage of identification of narrow active ranges, which may be erroneously skipped during regression analysis in conventional QSAR. Since the ultimate goal of modeling is to provide lead structures, therefore, active ranges of the proposed models can play a vital role in providing lead structures \[[@CR62]\]. Therefore, active ranges of the proposed models can naturally play a vital role in providing lead structures.

Conclusions {#Sec12}
===========

Diverse techniques such as DT, RF, SVM, and MAA were successfully used to develop models for anti-HIV purine nucleoside analogs. Models based on DT, RF, and SVM statistical approaches show an accuracy of prediction up to the order of 89 %. The overall accuracy of prediction of MAA-based models varies from 91.7 % to 96.9 % with regard to the anti-HIV activity of purine nucleoside analogs in human PBM cells. High values of sensitivity, specificity, and MCC indicate the robustness of the proposed models. Good predictability, high potency, and safety of the active ranges in the proposed MAA-based models will naturally provide ease in furnishing lead structures for the development of potent but safe anti-HIV purine nucleoside analogs.
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